Barry S. Coller, MD; Lesley E. Scudder, BS; Harvey J. Berger, MD; John D. Iuliucci, PhD
The F(ab′)2 fragment of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor (7E3) is a potent inhibitor of both in-vitro platelet aggregation and in-vivo platelet thrombus formation in animal studies. As a first step in assessing the potential of 7E3-F(ab′)2 as an antithrombotic agent for use in humans, we administered 7E3-F(ab′)2 intravenously at increasing doses to a person who had just died and was being maintained on a respirator (neomort). At 0.1 and at 0.2 mg/kg body weight, 74% and 92% of the glycoprotein IIb/IIIa receptors were blocked, respectively; adenosine-diphosphate-induced platelet aggregation was inhibited by 84% and 100% at these same doses. Platelet glycoprotein Ib function remained intact, even at 0.6 mg/kg. Acute hemodynamic or hemorrhagic toxicity was not noted. This antibody fragment, a potent, immediate-acting inhibitor of platelet aggregation, may be of benefit in vaso-occlusive and thromboembolic disorders.
Coller BS, Scudder LE, Berger HJ, Iuliucci JD. Inhibition of Human Platelet Function in Vivo with a Monoclonal Antibody: With Observations on the Newly Dead as Experimental Subjects. Ann Intern Med. ;109:635–638. doi: 10.7326/0003-4819-109-8-635
Download citation file:
© 2019
Published: Ann Intern Med. 1988;109(8):635-638.
DOI: 10.7326/0003-4819-109-8-635
Emergency Medicine, Infectious Disease, Mechanical Ventilation, Pulmonary/Critical Care.
Results provided by: